Alto Neuroscience ANRO Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $264.26M+49.3% | $176.98M+28.0% | $138.32M-6.6% | $148.09M-8.2% | $161.25M-4.4% | ||
| $269.13M+51.4% | $177.72M+27.4% | $139.45M-6.9% | $149.85M-8.4% | $163.52M-3.4% | ||
| $2.23M+19.3% | $1.87M-7.7% | $2.03M-12.1% | $2.31M-6.8% | $2.48M-7.1% | ||
| $276.26M+49.6% | $184.69M+25.6% | $147.01M-6.9% | $157.88M-8.2% | $171.92M-3.2% | ||
| $8.98M+28.4% | $6.99M+4.5% | $6.69M-2.8% | $6.89M-2.4% | $7.06M-12.7% | ||
| —— | —— | —— | —— | —— | ||
| $13.12M+15.8% | $11.33M+25.2% | $9.05M+11.3% | $8.13M+12.0% | $7.26M-27.5% | ||
| $13.89M-14.1% | $16.17M-20.4% | $20.31M+1.0% | $20.12M+0.9% | $19.94M+94.5% | ||
| $32.89M-2.0% | $33.55M-5.4% | $35.45M+2.9% | $34.47M+5.0% | $32.82M+25.8% | ||
| $3K0.0% | $3K0.0% | $3K0.0% | $3K0.0% | $3K0.0% | ||
| -$227.87M-13.0% | -$201.63M-8.7% | -$185.45M-8.3% | -$171.27M-11.5% | -$153.57M-11.0% | ||
| $243.37M+61.0% | $151.14M+35.5% | $111.56M-9.6% | $123.41M-11.3% | $139.1M-8.2% | ||
| $276.26M+49.6% | $184.69M+25.6% | $147.01M-6.9% | $157.88M-8.2% | $171.92M-3.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Alto Neuroscience's total assets?
- Alto Neuroscience (ANRO) holds $276.3M in total assets, up 60.7% year over year.
- How much debt does Alto Neuroscience have?
- Alto Neuroscience carries $20.9M in total debt against $243.4M of shareholders' equity, a debt-to-equity ratio of 0.09.
- How much cash does Alto Neuroscience have?
- Alto Neuroscience holds $264.3M in cash and equivalents.
- Can Alto Neuroscience cover its short-term obligations?
- Its current ratio is 20.52 — current assets exceed current liabilities.
- Where does Alto Neuroscience's balance sheet data come from?
- Every line is extracted from Alto Neuroscience's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.